Samantha L Kendrick, PhD, MS

Research Program: Cancer Biology Faculty Rank: Associate Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Biochemistry & Molecular Biology

Cancer Research Interest

• Disease Site Focus: Leukemia/ Lymphoma
• Research Focus Area: Treatment, Carcinogenesis
• Type of Research: Basic

Contact Information

• Email Address: SKENDRICK@UAMS.EDU
• Profiles Research Networking Software: View Profile

Active Grants

• American Cancer Society, Inc. – CAT-24-1374686-01-CAT
  “Impact of DNA topology on facilitating mutational events in lymphoma”
  Principal Investigator
  12/1/2024 – 11/30/2025
• National Science Foundation – 2341253
  “Replication of G-quadruplex DNA by translesion polymerases”
  Principal Investigator
  5/1/2024 – 4/30/2028
• US Department of Defense – W81XWH2211031
  “Targeting unique DNA structures to repress oncogenic signaling in lymphoma”
  Principal Investigator
  9/15/2022 – 9/14/2025
• NIH/Nat. Cancer Institute – 1R25CA250979
  “Partnership in Cancer Research (PCAR)”
  Principal Investigator
  9/1/2020 – 8/31/2025

Recent Publications

• Mehdi SH, Xu YZ, Shultz LD, [et al., including Kendrick S]. Development of New Diffuse Large B Cell Lymphoma Mouse Models. Cancers. 2024 16(17). PMID: 39272864. PMCID: PMC11394112.
• McCrury M, Swafford K, Shuttleworth SL, [et al., including Kendrick S]. Bifunctional inhibitor reveals NEK2 as a therapeutic target and regulator of oncogenic pathways in lymphoma. Molecular cancer therapeutics. 2023. PMID: 37816504. PMCID: PMC10932871.
• Chen J, Wang Z, Phuc T, [et al., including Kendrick S]. Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas. PLoS pathogens. 2023 19(1):e1011089. PMID: 36638143. PMCID: PMC9879403.
• Swafford K, Acharya B, Xu YZ, [et al., including Kendrick S]. Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group. Genes. 2022 13(7). PMID: 35885931. PMCID: PMC9321325.
• Chen J, Barrett L, Lin Z, [et al., including Kendrick S]. Identification of natural compounds tubercidin and lycorine HCl against small-cell lung cancer and BCAT1 as a therapeutic target. Journal of cellular and molecular medicine. 2022. PMID: 35318805. PMCID: PMC9077304.
• Chen J, Dai L, Kendrick S, [et al.]. The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways. Antimicrobial agents and chemotherapy. 2022:aac0239521. PMID: 35041508. PMCID: PMC8923226.
• Mohan M, Kendrick S, Szabo A, [et al.]. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood advances. 2021. PMID: 34807986. PMCID: PMC8945288.
• Mohan M, Szabo A, Yarlagadda N, [et al., including Kendrick S]. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. American journal of hematology. 2021. PMID: 34050985.
• Mohan M, Tackett A, Kumar M, [et al., including Kendrick S]. Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience. Bone. 2021 146:115876. PMID: 33556629. PMCID: PMC8627246.
• Brown SL, Kendrick S. The i-Motif as a Molecular Target: More Than a Complementary DNA Secondary Structure. Pharmaceuticals (Basel, Switzerland). 2021 14(2). PMID: 33513764. PMCID: PMC7911047.
• Xu YZ, Jenjaroenpun P, Wongsurawat T, [et al., including Kendrick S]. Activation-induced cytidine deaminase localizes to G-quadruplex motifs at mutation hotspots in lymphoma. NAR cancer. 2020 2(4):zcaa029. PMID: 33094287. PMCID: PMC7556405.
• Shponka V, Reveles CY, Alam S, [et al., including Kendrick S]. Frequent expression of activation-induced cytidine deaminase in diffuse large B-cell lymphoma tissues from persons living with HIV. AIDS (London, England). 2020 34(14):2025-2035. PMID: 32773475. PMCID: PMC9306295.